Teladoc Health Reports Fourth-Quarter and Full-Year 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Tech stocks bolster Wall Street as Nvidia quells AI growth concerns
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil rises by over $1 as White House says no US-Iran talks happening
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
- First Financial to acquire Hickory Point Bank in $111.3M deal
Teladoc (TDOC) Tops Q4 EPS by 7c, Revenues Beat; Offers Q1 & FY20 Revenue Guidance Above Consensus
February 26, 2020 4:05 PM ESTTeladoc (NYSE: TDOC) reported Q4 EPS of ($0.26), $0.07 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $156.49 million versus the consensus estimate of $152.95 million.
We demonstrated outstanding performance in the fourth quarter and full year of 2019 as we reported record results that were at the high end or exceeded our expectations on all key metrics. Our diversified growth strategies are driving strong growth across our channels, said Jason Gorevic, chief executive officer. Looking forward, we are... More
